The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease.

Journal Article (Journal Article;Review)

East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.

Full Text

Duke Authors

Cited Authors

  • Kim, HK; Tantry, US; Smith, SC; Jeong, MH; Park, S-J; Kim, MH; Lim, D-S; Shin, E-S; Park, D-W; Huo, Y; Chen, S-L; Bo, Z; Goto, S; Kimura, T; Yasuda, S; Chen, W-J; Chan, M; Aradi, D; Geisler, T; Gorog, DA; Sibbing, D; Lip, GYH; Angiolillo, DJ; Gurbel, PA; Jeong, Y-H

Published Date

  • April 2021

Published In

  • Thromb Haemost

Volume / Issue

  • 121 / 4

Start / End Page

  • 422 - 432

PubMed ID

  • 33171520

Electronic International Standard Serial Number (EISSN)

  • 2567-689X

Digital Object Identifier (DOI)

  • 10.1055/s-0040-1718729


  • eng

Conference Location

  • Germany